Wellesley Pharmaceuticals
2011
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Series D
LATEST DEAL TYPE
(In Progress)
$15M
LATEST DEAL AMOUNT
2
INVESTORS
Description
Developer of a drug designed to treat nocturia. The company's patented drug helps to treat the frequent need to urinate at night, enabling patients to sleep better at night without using the bathroom.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
- 3 Valley View Drive
- Newtown, PA 18940
- United States
+1 (215) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Wellesley Pharmaceuticals’s full profile, request a free trial.
Wellesley Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series D) | 18-Apr-2016 | $15M | 000.00 | 0000 | In Progress | Clinical Trials - Phase 2 |
| 3. Later Stage VC (Series C) | 01-Apr-2015 | 00.00 | 00.000 | 0000 | Completed | Clinical Trials - Phase 2 |
| 2. Angel (individual) | 01-Oct-2014 | $550K | $1.05M | 000.00 | Completed | Clinical Trials - Phase 2 |
| 1. Angel (individual) | 11-Jun-2014 | $500K | $500K | 000.00 | Completed | Clinical Trials - Phase 2 |
Wellesley Pharmaceuticals Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Axella Bioventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Keiretsu Forum | Venture Capital | Minority | 000 0000 | 000000 0 |
Wellesley Pharmaceuticals Executive Team (1)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| David Dill | Founder, Chief Executive Officer, President & Board Member |
Wellesley Pharmaceuticals Board Members (5)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Candan Karabagli | Self | Board Member | 000 0000 | |
| Christopher Lineberry | Self | Board Member | 000 0000 | |
| David Dill | Wellesley Pharmaceuticals | Founder, Chief Executive Officer, President & Board Member | 000 0000 | |
| Michael Myers Ph.D | Self | Board Member | 000 0000 | |
| Omer Karahan MD | Self | Board Member | 000 0000 |